MDT-AP-0530
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 39
- os_event
- false
- age_years
- 9.09
- sex
- M
- new_clusters
- C3
- umap1_2d
- 5.41584731
- umap2_2d
- 5.203223152
- umap1_3d
- 2.745651777
- umap2_3d
- -0.974387144
- umap3_3d
- -3.06263812
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.360
- KRAS_SIGNALING_DN+0.330
- MYOGENESIS+0.250
- WNT_BETA_CATENIN_SIGNALING+0.180
- ESTROGEN_RESPONSE_EARLY+0.170
- NOTCH_SIGNALING+0.150
- ESTROGEN_RESPONSE_LATE+0.140
- APICAL_SURFACE+0.110
- XENOBIOTIC_METABOLISM+0.100
- TGF_BETA_SIGNALING+0.090
Top 10 suppressed
- MYC_TARGETS_V1-0.520
- OXIDATIVE_PHOSPHORYLATION-0.500
- PROTEIN_SECRETION-0.380
- ALLOGRAFT_REJECTION-0.370
- INFLAMMATORY_RESPONSE-0.360
- MTORC1_SIGNALING-0.360
- IL6_JAK_STAT3_SIGNALING-0.340
- INTERFERON_GAMMA_RESPONSE-0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- UV_RESPONSE_DN-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_9CA93S6D | Diffuse intrinsic pontine glioma | — | 0.872 |
| 2 | 38aa467f-bd67-475e-9280-7e710bdc0cb3 | — | — | 0.848 |
| 3 | MDT-AP-0222 | Med | Medulloblastoma | 0.843 |
| 4 | MDT-AP-0179 | Med | Medulloblastoma | 0.830 |
| 5 | BS_YK6VQ9SJ | DNET | — | 0.829 |
| 6 | MNG660 | — | — | 0.828 |
| 7 | SRR4195667 | — | — | 0.828 |
| 8 | MDT-AP-1135 | Med | Medulloblastoma | 0.826 |
| 9 | MNG1257 | — | — | 0.825 |
| 10 | TCGA-D8-A3Z5-01A-41R-A24H-07 | — | A | 0.825 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.360 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.330 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.090 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.020 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.020 | Cobimetinib | — uncovered |
| P53_PATHWAY | 0.010 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |